BUPRENORPHINE

Brand name:

• Sublocade®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Indivior Pty Ltd

Condition/indication:
(therapeutic use)

• Opiate dependence

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (Minor)

Comment:

Application received a deferred outcome at a PBAC meeting prior to July 2019. No related medicine is available in the MSW.

Other PBAC consideration:

--

Submission received for:

Not applicable

Opportunity for consumer comment:

Not applicable

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/12/2019

Lodgement of required documentation:

23/12/2019

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/02/2020

Status:

Finalised

Government processes:

Commenced on 17/02/2020

Medicine listed on the PBS:

01/05/2020 (see PBS schedule)